$AVLN News

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate

Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead

Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

Assessing Avalyn Pharma (AVLN) Valuation As Investors React To Recent Share Price Moves

Avalyn to Participate in the Jefferies Global Healthcare Conference

Evercore ISI Group Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $51

Guggenheim Initiates Coverage On Avalyn Pharma with Buy Rating, Announces Price Target of $80

Morgan Stanley Initiates Coverage On Avalyn Pharma with Overweight Rating, Announces Price Target of $53

Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026

Avalyn Pharma To Present Updated Findings From ATLAS Open-Label Extension Trial Highlighting Long-Term Tolerability Profile Of AP01 For Treatment Of Pulmonary Fibrosis, At EULAR 2026

Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference

Avalyn To Present Findings From Usability Study For eFlow Nebulizer System At American Thoracic Society 2026 International Conference May 15-20

Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Is Avalyn Pharma (NASDAQ:AVLN) In A Good Position To Invest In Growth?

Avalyn Pharma Shares Open For Trade At $26/Share; IPO Priced At $18/Share On ~16.67M shares

Avalyn Announces Pricing of Upsized Initial Public Offering